- Home
- HFFG vs IPHA Comparison
HFFG vs IPHA Comparison
Compare HFFG & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HFFG
- IPHA
- Stock Information
- Founded
- HFFG N/A
- IPHA 1999
- Country
- HFFG United States
- IPHA France
- Employees
- HFFG N/A
- IPHA N/A
- Industry
- HFFG Food Distributors
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- HFFG Consumer Discretionary
- IPHA Health Care
- Exchange
- HFFG Nasdaq
- IPHA Nasdaq
- Market Cap
- HFFG 162.4M
- IPHA 191.0M
- IPO Year
- HFFG N/A
- IPHA 2019
- Fundamental
- Price
- HFFG $3.07
- IPHA $2.28
- Analyst Decision
- HFFG
- IPHA Strong Buy
- Analyst Count
- HFFG 0
- IPHA 1
- Target Price
- HFFG N/A
- IPHA $11.50
- AVG Volume (30 Days)
- HFFG 30.0K
- IPHA 5.5K
- Earning Date
- HFFG 11-07-2024
- IPHA 09-12-2024
- Dividend Yield
- HFFG N/A
- IPHA N/A
- EPS Growth
- HFFG N/A
- IPHA N/A
- EPS
- HFFG 0.07
- IPHA N/A
- Revenue
- HFFG $1,160,322,000.00
- IPHA $36,202,722.00
- Revenue This Year
- HFFG N/A
- IPHA N/A
- Revenue Next Year
- HFFG N/A
- IPHA $105.84
- P/E Ratio
- HFFG $42.20
- IPHA N/A
- Revenue Growth
- HFFG N/A
- IPHA 6.88
- 52 Week Low
- HFFG $2.46
- IPHA $1.81
- 52 Week High
- HFFG $5.91
- IPHA $3.15
- Technical
- Relative Strength Index (RSI)
- HFFG 44.66
- IPHA 50.55
- Support Level
- HFFG $3.08
- IPHA $2.22
- Resistance Level
- HFFG $3.31
- IPHA $2.41
- Average True Range (ATR)
- HFFG 0.23
- IPHA 0.12
- MACD
- HFFG -0.03
- IPHA 0.00
- Stochastic Oscillator
- HFFG 7.69
- IPHA 52.94
About HFFG HF Foods Group Inc.
HF Foods Group Inc is an Asian food service distributor that markets and distributes fresh produce, seafood, frozen and dry food, and non-food products to Asian restaurants and other food service customers throughout the United States. The Company's business consists of one operating segment; HF Group, which operates solely in the United States. The Company's customer base consists of Chinese and Asian restaurants, and it provides sales and service support to customers who mainly converse in Mandarin or Chinese dialects.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.